FDA red-faced over claims it is suppressing evidence

By Kirsty Barnes and Ahmed ElAmin

- Last updated on GMT

Related tags: Fda, Science, Food and drug administration, Pharmaceutical drug

The Food and Drug Administration (FDA) has been left red-faced
after a survey recently released by the Union of Concerned
Scientists (UCS), found a "disturbing level of interference in the
agency's research".

According to UCS, the survey "demonstrates a pervasive and dangerous political influence of science at the FDA."​ Almost 20 per cent of the nearly 1,000 scientists who responded anonymously to the survey said they had experienced their work manipulated or suppressed, having been "asked, for non-scientific reasons, to inappropriately exclude or alter technical information or their conclusions in an FDA scientific document."​ The scientists in question said they feared retaliation if they expressed their opinions in public, the UCS reported. Sixty-two percent of respondents were senior scientists, and nearly one-third of respondents had been agency employees for more than 15 years. Most of the allegations levelled by the scientists related to drug research, and this criticism and the survey's findings have important implications for the public's trust in the FDA's role in regulating the drug industry, and by implication in the safety of drug products. The USC survey found that 61 per cent of the respondents knew of cases where "Department of Health and Human Services or FDA political appointees have inappropriately injected themselves into FDA determinations or actions."​ Only 47 per cent of respondents think the "FDA routinely provides complete and accurate information to the public."​ About 81 per cent agreed that the "public would be better served if the independence and authority of FDA post-market safety systems were strengthened."​ About 70 per cent disagreed with the statement that FDA has sufficient resources to perform effectively its mission of "protecting public health…and helping to get accurate science-based information they need to use medicines and foods to improve their health."​ Many of the complaints were aimed at the agency's Office of Regulatory Affairs: one scientist said it should "not ostracise scientists or black ball them because their foresight sees a problem with a drug, device, food, biologics, etc. that possess a potential hazard to health now or in the future."​ Respondents also commented that budget cuts were affecting the agency's work and that it was being politicised instead of being based on scientific evidence. "We need more money. We need new equipment,"​ said one scientist. "We should be using the latest analysis techniques & modern technology instead of relying on conventional methods."​ Another commentator said: "Over the last several years I have noticed a significant increase in the number of decisions that have become politicized (e.g., increasing requests to review even simple regulations and changes, both by Congress and the Commissioner's office and to make apparently politically-motivated changes in language and sometimes to alter bottom line results), and I think the integrity of scientific work could be improved by minimising the 'politics' of the process."​ Another critic alleged: "I have seen violations that were not prosecuted because legal staff and/or management knew that the time required to prosecute some violations would take legal resources away from other violations that would have more immediate and severe health consequences."​ In a similar vein one of the respondents called for "increasing resources to permit FDA to maintain itself as a premier regulator of foods, drugs and cosmetics."​ The FDA is responsible for protecting public health through the regulation of drugs, food, medical devices, cosmetics, and the blood supply - including products that, according to the agency, account for 25 cents of every consumer dollar spent in the US. However, these latest revelations have further damaged the FDA's reputation, already tarnished after its involvement in high-profile safety lapses such as with Vioxx, the inflammatory drug withdrawn in 2004 after risks of heart attack and stroke were identified, as well as Ketek, an antibiotic found to have links to liver failure that was allegedly approved on the back of fraudulent clinical evidence.

Related news

Show more

Related products

show more

What should a clinical metadata repository do?

What should a clinical metadata repository do?

Formedix | 26-Jul-2021 | Technical / White Paper

Choosing a clinical metadata repository (MDR) software can be a tough task as the capabilities and features of your chosen MDR could make or break your...

Empowering Clinical Trial Sponsors with Analytics

Empowering Clinical Trial Sponsors with Analytics

PerkinElmer | 14-Jul-2021 | Technical / White Paper

Is your Clinical Data Review creating problems or solving them? Take Control of Your Data. PerkinElmer Informatics Clinical Solutions, powered by Tibco...

Related suppliers

Follow us


View more